09:59 AM


Not intended for U.S. and UK Media


Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) / Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) / QUASAR is expected to enroll around 800 patients in 27 countries / Study will add to the robust development program for aflibercept 8 mg, exploring the potential to achieve visual acuity with extended treatment intervals in additional patient populations